BioSpace News Archive

TG Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2019 and recent company developments.

Aerie Pharmaceuticals, Inc. announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:35 p.m. Eastern Time in New York, NY.

Phio Pharmaceuticals Corp. reported its financial results for the third quarter ended September 30, 2019 and provided a business update.

Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll, chief executive officer, will present at the following investor conferences:

Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an orally inhaled benzodiazepine for the acute termination of an ongoing prolonged focal, generalized or cluster seizure episode in patients who experience breakthrough seizures while on an antiepileptic drug, will participate in the Stifel 2019 Healthcare Conference in New York City.

Selecta Biosciences, Inc. announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the Stifel 2019 Healthcare Conference in New York on Tuesday, November 19 at 1:50 p.m. Eastern Time.

Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected by the end of 2019

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced the appointment of Maiken Keson-Brookes as chief legal officer and corporate secretary.

Continued progress on FUROSCIX®; confirming the planned resubmission of FUROSCIX® NDA with the FDA by mid-year 2020 remains on track

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Stifel 2019 Healthcare Conference at 9:10 a.m. ET on Tuesday, November 19, 2019, in New York.